Intragastric administration of the bitter tastant, quinine, reduces postprandial plasma glucose without affecting gastric emptying in health

PURPOSE: In health and type 2 diabetes, intraluminal administration of quinine stimulates glucoregulatory hormones and slows gastric emptying, key determinants of postprandial plasma glucose, following oral carbohydrate. We have now investigated these effects following a mixed solid-liquid meal, with gastric emptying quantified using scintigraphy, the 'gold-standard' technique. METHODS: Ga-EDTA), in randomised, double-blind fashion. Plasma glucose, insulin and glucagon were measured at baseline, for 60 min before, and for 120 min after, the meal. Gastric emptying was measured using scintigraphy. Data were analysed using repeated-measures ANOVA. RESULTS: Q600 and Q300 both reduced plasma glucose immediately before the meal, at t=-5 min, as well as overall and peak postprandial glucose, when compared with control, in a dose-dependent manner (P < 0.05). Q600 stimulated plasma insulin before the meal at t=-20 min (P = 0.04), and the postprandial plasma insulin-to-glucose ratio (P = 0.02), compared with control. Both overall and peak postprandial plasma glucose were inversely related to plasma insulin at t=-20 min (R<-0.51, P < 0.05). Quinine did not affect plasma glucagon or gastric emptying. CONCLUSION: Intragastric quinine lowers the plasma glucose response to a mixed solid-liquid meal in middle-aged individuals without diabetes by stimulating preprandial insulin, without affecting either plasma glucagon or gastric emptying. TRIAL REGISTRATION: The study was registered as a clinical trial with the Australian and New Zealand Clinical Trials Registry ( https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=383933&isReview=true ; ACTRN12622000735752, date of registration: May 23, 2022).

Authors

Institutions

Publication Details

Journal
European Journal of Nutrition
Published
2026-11-18
DOI
https://doi.org/10.1007/s00394-026-04170-w
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Intragastric administration of the bitter tastant, quinine, reduces postprandial plasma glucose without affecting gastric emptying in health

Vida Bitarafan, Javad Anjom-Shoae, Penelope C. E. Fitzgerald, Karen L. Jones et al.
2 links
European Journal of Nutrition
Diabetes Treatment and Management
article

Intragastric administration of the bitter tastant, quinine, reduces postprandial plasma glucose without affecting gastric emptying in health

Vida Bitarafan, Javad Anjom-Shoae, Penelope C. E. Fitzgerald, Karen L. Jones, Parivash Ghorbaninejad, Christine Feinle‐Bisset, Braden D. Rose, Michael Horowitz, Seva Hatzinikolas, Maedeh Moradi
article en

Abstract

PURPOSE: In health and type 2 diabetes, intraluminal administration of quinine stimulates glucoregulatory hormones and slows gastric emptying, key determinants of postprandial plasma glucose, following oral carbohydrate. We have now investigated these effects following a mixed solid-liquid meal, with gastric emptying quantified using scintigraphy, the 'gold-standard' technique. METHODS: Ga-EDTA), in randomised, double-blind fashion. Plasma glucose, insulin and glucagon were measured at baseline, for 60 min before, and for 120 min after, the meal. Gastric emptying was measured using scintigraphy. Data were analysed using repeated-measures ANOVA. RESULTS: Q600 and Q300 both reduced plasma glucose immediately before the meal, at t=-5 min, as well as overall and peak postprandial glucose, when compared with control, in a dose-dependent manner (P < 0.05). Q600 stimulated plasma insulin before the meal at t=-20 min (P = 0.04), and the postprandial plasma insulin-to-glucose ratio (P = 0.02), compared with control. Both overall and peak postprandial plasma glucose were inversely related to plasma insulin at t=-20 min (R<-0.51, P < 0.05). Quinine did not affect plasma glucagon or gastric emptying. CONCLUSION: Intragastric quinine lowers the plasma glucose response to a mixed solid-liquid meal in middle-aged individuals without diabetes by stimulating preprandial insulin, without affecting either plasma glucagon or gastric emptying. TRIAL REGISTRATION: The study was registered as a clinical trial with the Australian and New Zealand Clinical Trials Registry ( https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=383933&isReview=true ; ACTRN12622000735752, date of registration: May 23, 2022).

European Journal of NutritionVol. 65(8)
Royal Adelaide Hospital (AU), South Australian Health and Medical Research Institute (AU), Adelaide University (AU), The University of Adelaide (AU)
National Health and Medical Research Council
Good health and well-being
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon